UTRECHT, The Netherlands , Dec. 27, 2017 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics ® ), today announced that the United States Court of Appeals for the Federal Circuit denied Regeneron

UTRECHT, The Netherlands , Nov. 30, 2017 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics ® ), today announced financial results for the third quarter ended September 30, 2017 and provided a

UTRECHT, The Netherlands , Nov. 09, 2017 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced that Ton Logtenberg, CEO, will present at the Jefferies London Healthcare Conference on Thursday,

UTRECHT, The Netherlands , Oct. 10, 2017 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced that Ton Logtenberg, Ph.D., Chief Executive Officer, will be participating in the 2017 BIO Investor

UTRECHT, The Netherlands , Sept. 20, 2017 (GLOBE NEWSWIRE) -- Merus (NASDAQ:MRUS), a clinical-stage immuno-oncology company developing therapeutics with the goal of treating and curing serious illnesses, announced today that it has added to its deep intellectual property portfolio two new U.S.

UTRECHT, The Netherlands , Sept. 19, 2017 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics ® ), today announced financial results for the second quarter ended June 30, 2017 and provided a

UTRECHT, The Netherlands , Aug. 30, 2017 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced that Ton Logtenberg, Ph.D., Chief Executive Officer, will participate at two upcoming

UTRECHT, The Netherlands , Aug. 09, 2017 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced that Ton Logtenberg, Ph.D., Chief Executive Officer, will present a company overview

UTRECHT, The Netherlands , July 28, 2017 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics ® ), today announced that the U.S. Court of Appeals for the Federal Circuit affirmed the trial court’s

Balance sheet strengthened with $120 million upfront payment and an $80 million share purchase from Incyte Corporation for global strategic research collaboration to discover and develop bispecific antibodies Based on single agent activity in the MCLA-128 Phase 1/2 clinical trial, Phase 2

Conference call and webcast scheduled on 4:30pm ET UTRECHT, The Netherlands , July 06, 2017 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced that the company will provide an

Utrecht, The Netherlands— June 2017 —Ton Logtenberg, Founder and Chief Executive Officer of Merus N.V. will participate in a BioPharma Dealmakers webcast, sponsored in part by Merus N.V., featuring three other companies innovating cancer immunotherapy.

UTRECHT, The Netherlands , June 01, 2017 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced that Ton Logtenberg, Ph.D., Chief Executive Officer, will present a company overview at the

Results to be presented at the 2017 American Society of Clinical Oncology Annual Meeting Phase 2 clinical trial to be initiated in second half of 2017 exploring two metastatic breast cancer populations: HER2-positive patients and hormone receptor-positive/HER2-low patients UTRECHT, The Netherlands

UTRECHT, The Netherlands , May 09, 2017 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced that the Annual General Meeting of Shareholders will be held on Wednesday, May 24 ,

In a release issued April 28, 2017 by Merus N.V. (Nasdaq:MRUS) with the same headline, an error was made such that the figures for the three months ended December 31, 2016 in the “Consolidated Statement of Profit or Loss and Comprehensive Loss” table were incorrect.

UTRECHT, The Netherlands , April 28, 2017 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced financial results for the fourth quarter and full year ended December 31, 2016 and provided a

UTRECHT, The Netherlands , April 20, 2017 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced that data from a Phase 1/2 study of MCLA-128 for the treatment of metastatic breast cancer will be

Award Recognizes Company’s Substantial Transformation and Breakthroughs Over Past 12 Months UTRECHT, The Netherlands , March 16, 2017 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced that

UTRECHT, The Netherlands , Feb. 27, 2017 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced that Ton Logtenberg, Ph.D., Chief Executive Officer, will present a company overview at the Cowen

UTRECHT, The Netherlands , Feb. 09, 2017 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced that Ton Logtenberg, Ph.D., Chief Executive Officer, will participate at the Leerink Partners 6 th

UTRECHT, The Netherlands , Jan. 23, 2017 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS) a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced the closing of its global strategic research collaboration with Incyte Corporation (NASDAQ:INCY)

UTRECHT, The Netherlands , Jan. 05, 2017 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, and the Institute for Research in Biomedicine (IRB) Barcelona , a research center devoted to understanding